newsfilter
← Latest News
Business Wire·

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

– The review provides strong scientific rationale to support Alto's drug development approach leveraging its Precision Psychiatry Platform – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage